Sickle Cell Disease - Epidemiology Forecast - 2032

Key Highlights

• Sickle cell disease (SCD) is a genetic blood disorder characterized by the presence of abnormal hemoglobin, causing red blood cells to become sickle-shaped. This abnormal shape leads to complications, including chronic pain, organ damage, and increased susceptibility to infections. SCD is a global health concern, particularly prevalent in populations with African, Middle Eastern, Mediterranean, and South Asian ancestry.
• The primary cause of SCD is a mutation in the HBB gene, which affects the production of hemoglobin. Individuals with SCD inherit two copies of the mutated gene, one from each parent, resulting in abnormal hemoglobin production. The abnormal red blood cells tend to become rigid and sticky, obstructing blood flow and causing episodes of intense pain called sickle cell crises.
• SCD poses significant challenges for affected individuals, impacting their quality of life and life expectancy. Common complications include anemia, acute chest syndrome, stroke, organ damage (e.g., kidneys, liver), and increased susceptibility to infections. These complications require comprehensive management, including pain relief, blood transfusions, antibiotic prophylaxis, and interventions to prevent and treat complications.
• The total prevalent cases of SCD trait in the US comprised ~4,169,000 in 2019 and are projected to reach ~4,561,000 cases by 2032.
• In 2019, the total prevalent cases of sickle cell disease EU4 and the UK were, in the Germany, France, Italy, Spain and UK were estimated to be ~3,100, ~26,200, ~9,900, ~1,000, and ~15,300 cases which as per the publisher's estimates, will increase to ~3,200, ~27,000, ~10,100, ~1,000 and ~16,000 cases total prevalent cases of sickle cell disease by 2032.
• This “Sickle Cell Disease (SCD) - Epidemiology Forecast - 2032” report delivers an in-depth understanding of SCD, historical and forecasted epidemiology in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom

Geography Covered

• The United States
• EU4 (Germany, France, Italy, and Spain) and the United Kingdom

Study Period: 2019-2032

Sickle Cell Disease (SCD) Disease Understanding and Diagnostic Algorithm

Sickle Cell Disease (SCD) Overview

Sickle Cell Disease (SCD) is a group of lifelong inherited conditions that affect hemoglobin. It is characterized as a chronic hemolytic disorder marked by the tendency of hemoglobin molecules within red blood cells to polymerize and deform the red cell into sickle (or crescent) shape (Hb S), resulting in characteristic vaso-occlusive events and accelerated hemolysis.

The first description of clinical signs and symptoms of sickle cell disease was given by Dr. Horton, a Sierra Leonian medical doctor, in 1874 and is described as “peculiar elongated and sickle-shaped red blood corpuscles causing severe anemia.” Sickle cell disease is caused by abnormal hemoglobin, referred to as "hemoglobin S." The disease was among the first to be understood fully at the biochemical level, as researchers learned that the abnormal hemoglobin was changing shape (called "sickling") due to a single amino acid error in hemoglobin S.

Sickle Cell Disease (SCD) Diagnosis

Sickle cell disease diagnosis starts with a blood test that is analyzed for defective genes or hemoglobin cells. Various screening programs are also there which help in early diagnosis of the disease during the prenatal or infancy period.

• Blood tests

A person can go for the screening blood test to differentiate sickle hemoglobin (hemoglobin S) or another hemoglobin (such as C, ß-thalassemia, E).

• Newborn screening

Diagnosing SCD early in a child is very important to prevent further complications. All babies born in most developed countries are offered screening for sickle cell disease shortly following the birth.

• DNA analysis

This test can be used to investigate alterations and mutations in the gene that produces hemoglobin components. This test may be performed to determine whether someone has one or two copies of the Hb S mutation or has two different mutations in hemoglobin genes (e.g., Hb S and Hb C).

Further details related to country-based variations are provided in the reported

Sickle Cell Disease (SCD) Epidemiology

The Sickle Cell Disease (SCD) epidemiology chapter in the report provides historical as well as forecasted epidemiology segmented by Total Prevalent Cases of SCD Trait, Total Prevalent Cases of SCD, Diagnosed Cases of SCD, Age-specific Cases of SCD, and Type-specific Cases of SCD in the 6MM, covering the United States, EU4 countries (Germany, France, Italy, and Spain) and the United Kingdom from 2019 to 2032.

• In 2022, the total prevalent cases of Sickle Cell Disease in the United States were found to be ~104,900 which as per the publisher's estimates, will increase by 2032, with a mild CAGR.
• In 2022, Italy accounted for ~7,500 cases of diagnosed cases of SCD, accounting for around 5% of the total diagnosed cases in the 6MM,
• In 2022, Germany accounted for ~2,100 cases of diagnosed cases of SCD, which was approximately 1% of the total diagnosed cases of SCD in the 6MM.
• As per the publisher's estimates sickle cell disease was most prevalent in the 18-44 years of age group. In 2022, the age-specific cases of SCD in the France were ~4,700; ~6,900; ~5,900, and ~4,400 in the age groups of 0-17 years, 18-44 years, 45-64 years, and 65 years and above, respectively, which will increase by 2032.

Scope of the Report

• The report covers a segment of key events, an executive summary, and a descriptive overview of Sickle Cell Disease, explaining its causes, signs and symptoms, pathogenesis, and currently available therapies.
• Comprehensive insight into the epidemiology segments and forecasts, the future growth potential of diagnosis rate, and disease progression have been provided.
• A detailed review of current challenges in establishing diagnosis and diagnosis rate is provided.

Sickle Cell Disease (SCD) report insights

• Patient population
• Prevalence pattern
• Diagnosis rate
• Country-wise epidemiology distribution

Sickle Cell Disease (SCD) report key strengths

• Ten years forecast
• The 6MM coverage
• Sickle Cell Disease (SCD) epidemiology segmentation

Sickle Cell Disease (SCD) report assessment

• Epidemiology segmentation
• Current diagnostic practices

Key Questions Answered

Epidemiology insights

• What are the disease risk and burdens of Sickle Cell Disease? What will be the growth opportunities across the 6MM with respect to the patient population of Sickle Cell Disease?
• What is the historical and forecasted Sickle Cell Disease (SCD) patient pool in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom?
• Why are only limited patients with symptoms treated?
• What factors are affecting the increase in the diagnosis of symptomatic cases?

Reasons to Buy

• The report will help develop business strategies by understanding the latest trends and changing epidemiology dynamics driving the Sickle Cell Disease.
• Insights on patient burden/disease prevalence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
• To understand the perspective of Key Opinion Leaders around the current challenges with establishing the diagnosis and current diagnosis rate of the eligible patient pool.